Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (17447)	3/14/1998 6:01:00 PM
From: squetch	Respond to of 32384

There is a letter, not a paper, in the recent issue of JClinEndocrinology which states >>We here report another possible benefit of troglitazone, prevention of atherosclerosis<< I didn't read it very well tho.

To: Henry Niman who wrote (17447)	3/15/1998 2:49:00 AM
From: John O'Neill	Respond to of 32384

Henry N. Do you have an opinion on MLNM? Here's a post from the MLNM thread. I hope the author doesn't mind me posting it here.... To: John O'Neill (114 ) From: Pseudo Biologist Friday, Mar 13 1998 4:14PM EST Reply # of 120 John, yes. Henry could say one or two things about MLNM, as they were in the running for the cloning of the leptin receptor (a tiny outfit called Progenitor - PGEN- may have cloned at about the same time). We've talked about Microcide before, and I hold a small position on it. Interesting company, but they better put something in the clinic this year or you will see many disappointed investors. One thing that blew me away in the MLNM web page is the number (and nature) of job openings. These guys spend money like crazy; I hope they have the contract or otherwise revenues to feed all those people. Two recent appointments at MLNM are interesting to me. One was Crhis Sander to head the bioinformatics division. Sander has excellent reputation in the structural biology field; I was surprised he would leave his cozy position at the EMBL (kind of like a European NIH, roughly) to work for this "small" biotech. The other is Michael Pavia from Sphynx, the combinatorial chemistry subsidiary of Lilly. This suggests they are making enough progress in target discovery that they want to start doing chemistry. The ChemGenics acquisition also fits this strategy. PB